Skip to main content
Premium Trial:

Request an Annual Quote

Premaitha Names Adgenix as NIPT Distributor in France

NEW YORK (GenomeWeb) – Premaitha Health said today that it has named Adgenix as the exclusive distributor of its Iona cell-free DNA prenatal screening test in France.

In addition, Premaitha, based in Manchester, UK, said that Adgenix has already signed up its first laboratory customer, inking a contract for a minimum of three years to supply LaboSud with the assay.

The Iona test estimates the risk of a fetus being affected by Down syndrome and other serious genetic conditions by analyzing cell-free fetal DNA from a maternal blood sample. The test enables clinical laboratories to offer their own decentralized non-invasive prenatal testing in house, thereby providing faster results to the patient.

"Securing our first French partnership with LaboSud and Adgenix is an important step forward for us as we continue to expand the reach of the Iona test across Europe," Premaitha CEO Stephen Little said in a statement. "Our NIPT test provides more accurate and faster results that will benefit more pregnant women in France."

LaboSud is a private group of reference laboratories in the Montpellier region of France. It provides medical and diagnostic laboratory services to clinics and hospitals from the Languedoc-Roussillon region with plans to expand throughout the country.

The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.